Welcome to our dedicated page for Proqr Therapeuti news (Ticker: PRQR), a resource for investors and traders seeking the latest updates and insights on Proqr Therapeuti stock.
ProQR Therapeutics N.V. reports developments as a clinical-stage biopharmaceutical company built around its proprietary Axiomer™ RNA editing platform. The technology uses ADAR-mediated RNA editing to make single-nucleotide changes in RNA, with pipeline updates centered on AX-0810 and additional programs across rare and prevalent diseases with unmet need.
Recurring company news includes scientific conference presentations, investor and analyst events, clinical-program updates, development-candidate selections, AI-enabled discovery initiatives, and collaborations such as Ginkgo Bioworks and Eli Lilly. ProQR also reports annual operating and financial results, annual general meeting materials, board composition changes, and other governance matters tied to its Nasdaq-listed public-company profile.
ProQR Therapeutics N.V. (Nasdaq: PRQR) has announced a strategic shift focusing on its Axiomer® RNA editing technology after receiving guidance from the European Medicines Agency (EMA) regarding sepofarsen. An additional pivotal trial for sepofarsen is now required prior to a Marketing Authorisation Application. The company will seek a strategic partner for its ophthalmology assets while winding down current trials, which will lead to workforce reductions but extend its cash runway into 2026.
ProQR Therapeutics has accelerated its Axiomer® RNA base-editing technology and plans to update on initial targets in H2 2022. The company is in discussions with the EMA and FDA regarding data from the Illuminate trial and the regulatory path for ultevursen. Ongoing enrollment in the Sirius Phase 2/3 trial for USH2A-mediated Usher syndrome continues. Financially, ProQR reported €156.4 million in cash as of June 30, 2022, with a net loss of €14.7 million for the quarter. R&D expenses increased to €11.4 million compared to last year.
ProQR Therapeutics N.V. (Nasdaq: PRQR) announced its participation in the Life Sci 2nd Annual Genetic Medicines Symposium on June 29, 2022, focusing on the RNA Editing track. The presentation will be webcast live from 10:00 to 10:30 am EDT and available for replay for 30 days. ProQR is pioneering RNA therapies using their Axiomer® technology, aiming to create transformative medicines for genetic diseases. More details can be found on ProQR’s official website.
ProQR Therapeutics (Nasdaq: PRQR) announced key leadership changes and the Annual General Meeting (AGM) on June 30, 2022. René Beukema joins as Chief Corporate Development Officer and General Counsel, while Gerard Platenburg takes on the Chief Scientific Officer role overseeing the Axiomer® RNA-editing platform. John Maraganore extends his role as a strategic advisor to the Supervisory Board. Smital Shah will leave the company at the end of 2022, with a search for a new CFO underway. The company focuses on advancing its RNA therapies and Axiomer technology.
ProQR Therapeutics N.V. (Nasdaq: PRQR) announced its participation in the TIDES USA conference from May 9-12, 2022, in Boston, MA. Gerard Platenburg, Co-Founder and Chief Innovation Officer, will present an oral presentation titled Development of RNA Base Editing Technologies for Precision Medicines on May 11, 2022, at 11:15 AM EDT. ProQR is advancing RNA therapies with its proprietary Axiomer® technology, which utilizes the body's own editing system, ADAR, to create targeted RNA modifications, potentially leading to novel treatments for genetic disorders.
ProQR Therapeutics reported Q1 2022 results, revealing a net loss of €14.5 million, or €0.20 per diluted share. The company's cash reserves stood at €167.6 million, down from €187.5 million in Q4 2021. Key highlights include ongoing trials for sepofarsen and ultevursen, with encouraging post-hoc efficacy data from the Illuminate trial. ProQR plans to meet with the EMA and FDA in Q3 to discuss findings and intends to expand its Axiomer RNA editing platform beyond ophthalmology.
Financially, R&D costs increased to €13.4 million from €8.9 million year-over-year.
ProQR Therapeutics (Nasdaq: PRQR) announced presentations at the 7th Annual Retinal Cell and Gene Therapy Innovation Summit on April 29, 2022, and the ARVO Annual Meeting from May 1-4, 2022, in Denver, CO. Dr. Artur Cideciyan presented on AON treatment for CEP290-LCA, while Dr. Bart Leroy discussed the efficacy of sepofarsen in treating LCA10. Notable presentations include long-term safety data and genetic therapies aimed at restoring vision in rare inherited diseases. The company focuses on delivering transformative RNA therapies to combat severe genetic conditions.
ProQR Therapeutics N.V. (Nasdaq: PRQR) announced its participation in the Kempen Life Sciences Conference scheduled for April 20, 2022. The company specializes in transformative RNA therapies, utilizing a unique technology called Axiomer® to edit RNA and potentially treat genetic diseases. ProQR aims to develop innovative medicines using its proprietary RNA repair platform, prioritizing patient needs. For further details, visit www.proqr.com.
ProQR Therapeutics (PRQR) announced encouraging post-hoc analyses from the Illuminate trial of sepofarsen, indicating efficacy when comparing treated and untreated eyes. The company plans to engage with regulators in Q3 regarding these findings. ProQR's strategy now focuses on accelerating its Axiomer® RNA base-editing platform and selected inherited retinal disease programs, along with a 30% workforce reduction to extend its cash runway into 2025. Despite setbacks in achieving the primary endpoint of the Illuminate trial, the results support ongoing development and further regulatory discussions.
On April 4, 2022, ProQR Therapeutics (Nasdaq: PRQR) announced its participation in the 3rd RNA Editing Summit in Boston, MA. Co-founder Gerard Platenburg will present Axiomer®, a proprietary RNA base editing platform, on April 6 at 11:00am ET. This innovative technology utilizes the body's ADAR editing machinery to reverse disease-causing RNA mutations. Axiomer® has broad potential, targeting genetic diseases like Leber congenital amaurosis and Usher syndrome, with a strong patent portfolio reinforcing its promise in treating previously untreatable conditions.